DE69328087T2 - Verwendung von ibuprofen-beta-cyclodextrin-komplex für die orale verabreichung - Google Patents

Verwendung von ibuprofen-beta-cyclodextrin-komplex für die orale verabreichung

Info

Publication number
DE69328087T2
DE69328087T2 DE69328087T DE69328087T DE69328087T2 DE 69328087 T2 DE69328087 T2 DE 69328087T2 DE 69328087 T DE69328087 T DE 69328087T DE 69328087 T DE69328087 T DE 69328087T DE 69328087 T2 DE69328087 T2 DE 69328087T2
Authority
DE
Germany
Prior art keywords
ibuprofen
beta
pct
cyclodextrin complex
oral administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69328087T
Other languages
English (en)
Other versions
DE69328087D1 (de
Inventor
Timothy James Grattan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of DE69328087D1 publication Critical patent/DE69328087D1/de
Application granted granted Critical
Publication of DE69328087T2 publication Critical patent/DE69328087T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69328087T 1992-04-10 1993-04-02 Verwendung von ibuprofen-beta-cyclodextrin-komplex für die orale verabreichung Expired - Lifetime DE69328087T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929207990A GB9207990D0 (en) 1992-04-10 1992-04-10 Pharmaceutical composition
PCT/GB1993/000702 WO1993020850A1 (en) 1992-04-10 1993-04-02 Pharmaceutical composition

Publications (2)

Publication Number Publication Date
DE69328087D1 DE69328087D1 (de) 2000-04-20
DE69328087T2 true DE69328087T2 (de) 2000-08-24

Family

ID=10713877

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69328087T Expired - Lifetime DE69328087T2 (de) 1992-04-10 1993-04-02 Verwendung von ibuprofen-beta-cyclodextrin-komplex für die orale verabreichung

Country Status (13)

Country Link
US (1) US5597583A (de)
EP (1) EP0633787B1 (de)
JP (1) JPH07505645A (de)
KR (1) KR950700762A (de)
AT (1) ATE190505T1 (de)
AU (1) AU667095B2 (de)
CA (1) CA2117762A1 (de)
DE (1) DE69328087T2 (de)
ES (1) ES2145772T3 (de)
GB (1) GB9207990D0 (de)
HK (1) HK1012260A1 (de)
NZ (1) NZ251393A (de)
WO (1) WO1993020850A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2190598A1 (en) * 1994-05-27 1995-12-07 Lawrence John Penkler Pharmaceutical composition
GB9625589D0 (en) * 1996-12-10 1997-01-29 Boots Co Plc Therapeutic agents
IT1301966B1 (it) 1998-07-30 2000-07-20 Zambon Spa Composizioni farmaceutiche ad attivita' analgesica
US6211246B1 (en) * 1999-06-10 2001-04-03 Mcneil-Ppc, Inc. Rapidly absorbed liquid compositions
ES2171110B1 (es) * 2000-03-03 2003-06-16 Aplicaciones Farmacodinamicas Composicion farmaceutica a base de ibuprofeno y procedimiento para su preparacion.
CN1446316A (zh) * 2000-08-02 2003-10-01 玛洛普有限公司 基于下丘脑-垂体-肾上腺轴异常的非溃疡性消化不良的诊断和处置
EP1411899B1 (de) * 2001-08-01 2009-03-11 Novartis AG Zusammensetzung zur maskierung des geschmacks
KR100567131B1 (ko) * 2004-01-05 2006-04-05 신일제약주식회사 쓴맛을 차폐한 아르기닌 함유 이부프로펜 경구투여 액상조성물
WO2007055887A1 (en) * 2005-11-02 2007-05-18 Teikoku Pharma Usa, Inc. Organoleptically acceptable ibuprofen oral dosage formulations, methods of making and using the same
US20070207206A1 (en) * 2006-03-02 2007-09-06 Rice Bronwyn C Chewable pain formula
JP5242543B2 (ja) * 2006-03-16 2013-07-24 ノバルティス アーゲー 味をマスキングした活性薬剤を含有する固体剤形
JP5977672B2 (ja) * 2009-04-27 2016-08-24 ラボラトリオ デ アプリカシオネス ファルマコディナミカス,エセ.アー.Laboratorio De Aplicaciones Farmacodinamicas,S.A. イブプロフェンリシナートの経口投与用の懸濁液
HUE029953T2 (en) * 2009-04-27 2017-04-28 Laboratorio De Aplicaciones Farm S A Oral ibuprofen lysate suspension
CN114588107B (zh) * 2022-04-06 2023-04-18 河北一品生物医药有限公司 一种布洛芬赖氨酸盐注射液及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43290B (en) * 1986-11-13 1989-06-30 Lek Tovarna Farmacevtskih Process for preparing inclusioned complex of ibuproxane with beta-cyclodextrine
CA1298290C (en) * 1987-01-09 1992-03-31 Herand M. Markarian Solution ibuprofen complexes, compositions and processes for preparing the same
GB8813682D0 (en) * 1988-06-09 1988-07-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
US5024997A (en) * 1990-06-22 1991-06-18 American Home Products Corporation Palatable ibuprofen solutions
DE4038314A1 (de) * 1990-11-30 1992-06-04 Puetter Medice Chem Pharm Komplexe des aktiven enantiomers des ibuprofens mit cyclodextrin

Also Published As

Publication number Publication date
AU3898793A (en) 1993-11-18
NZ251393A (en) 1996-08-27
HK1012260A1 (en) 1999-07-30
EP0633787B1 (de) 2000-03-15
EP0633787A1 (de) 1995-01-18
CA2117762A1 (en) 1993-10-28
ATE190505T1 (de) 2000-04-15
DE69328087D1 (de) 2000-04-20
GB9207990D0 (en) 1992-05-27
WO1993020850A1 (en) 1993-10-28
US5597583A (en) 1997-01-28
AU667095B2 (en) 1996-03-07
KR950700762A (ko) 1995-02-20
JPH07505645A (ja) 1995-06-22
ES2145772T3 (es) 2000-07-16

Similar Documents

Publication Publication Date Title
ATE190505T1 (de) Verwendung von ibuprofen-beta-cyclodextrin- komplex für die orale verabreichung
DE69115280D1 (de) Indolderivate, die die leukotrienbiosynthese hemmen.
DE69111077T2 (de) Chinazolinderivate um die antitumorwirkung zu verbessern.
ATE163418T1 (de) Risperidon pamoate
TR199700844T1 (xx) Pirazolil-Benzoil T�revleri.
ATE167476T1 (de) Substituierte 2-phenyl-3-methocypropensäurenester als fungizide mittel.
FI942313A (fi) Välituote atsitromysiiniä varten
IL118167A0 (en) Pyrazolo (1,5a) pyrimidines their preparation and use
DE69225410D1 (de) Herstellung von n-acetylneuraminsäure-derivaten
DE69224295D1 (de) Pestizid und fungizid
MX9401406A (es) Agentes receptores de adenosina selectivos para intensificar el conocimiento.
FI102185B1 (fi) Anionisten diatsoväriaineiden konsentroidut, vesipitoiset liuokset
NO941084D0 (no) Neuroleptiske 2-substituerte perhydro-1-H-pyrido[1,2-aÅpyraziner
TR26431A (tr) ANIYONIK AZO BOYAR MADDELERININ KONSANTRE, SULU CÖZELTILERININ üRETILMESINE MAHSUS USUL.
FI934977A (fi) Foerfarande foer att reducera elkfoerbrukningen i mikroprocessorbaserade,isynnerhet foer publika telefonstationer avsedda anordningar
DE69512087D1 (de) Monoazopigmente
ES2128426T3 (es) Retinoides acuosolubles.
MX9201288A (es) Metodo de tratamiento.
NO974687D0 (no) Kondenserte <beta>-carboliner
GR3023147T3 (en) New triazoloquinazolines, their production and their use.